Taiho Oncology, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2002-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.taihooncology.com
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
- Conditions
- Interventions
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04953897
- Locations
- 🇵🇱
Centrum Badań Klinicznych Piotr Napora Lekarze Sp. p., Wrocław, Poland
🇷🇴Institutul Oncologic Bucuresti - Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania
🇷🇴Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania
TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04770246
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
🇺🇸Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 492
- Registration Number
- NCT04737187
- Locations
- 🇺🇸
Investigative Clinical Research of Indiana LLC, Noblesville, Indiana, United States
🇦🇹"Landeskrankenhaus Feldkirch Interne E", Rankweil, Austria
🇺🇸Mayo Clinic - FL, Jacksonville, Florida, United States
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT04657081
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States
🇺🇸Boca Raton Clinical Research, Plantation, Florida, United States
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT04601857
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇫🇷Institut Paoli Calmettes - Hôpital de jour, Marseille, Bouches-du-Rhône, France
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04586270
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇫🇷Institut Paoli Calmette, Marseille, Bouches Du Rhone, France
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
- Conditions
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Registration Number
- NCT04507503
- Locations
- 🇺🇸
Banner MD Anderson, Gilbert, Arizona, United States
🇺🇸Aurora Cancer care, Grafton, Wisconsin, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of TAS1440 With ATRA in Subjects With r/r AML
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04282668
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center Site#105, Seattle, Washington, United States
🇺🇸University of Michigan Medical School Site#107, Ann Arbor, Michigan, United States
🇺🇸Oregon Health and Science University Site#111, Portland, Oregon, United States
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 317
- Registration Number
- NCT04256317
- Locations
- 🇺🇸
Keck School of Medicine of USC, Los Angeles, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
Futibatinib in Patients With Specific FGFR Aberrations
- Conditions
- Interventions
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT04189445
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa-shi, Chiba-Ken, Japan
🇺🇸Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City, Oklahoma, United States
🇮🇹Ospedale Sacro Cuore Don Calabria, Negrar, Verona, Italy